The seroprevalence of antibodies to Japanese encephalitis virus in five New South Wales towns at high risk of infection, 2022: a cross‐sectional serosurvey
- Published on 18/02/2025
- Reading time: 4 min.
Zoe Baldwin 1,2, Linda Hueston 3, April Roberts‐Witteveen 4, Priscilla Stanley 5, Meru Sheel 6, Noni Winkler 7, Archana Koirala 7,8, Kristine Macartney 7,9, Jennifer Case 10, Kirsty Hope 10, Keira M Glasgow 10
1
National Centre for Epidemiology and Population Health
Australian National University
Canberra
ACT
2
Hunter New England Local Health District
Newcastle
NSW
3
CIDMLS Institute of Clinical Pathology and Medical Research
Sydney
NSW
4
Southern and Murrumbidgee Local Health District
Goulburn
NSW
5
Western New South Wales Local Health District
Dubbo
NSW
6
Sydney School of Public Health
University of Sydney
Sydney
NSW
7
National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases
Sydney
NSW
8
Nepean Hospital, Nepean Blue Mountains Local Health District
Penrith
NSW
9
The University of Sydney
Sydney
NSW
10
New South Wales Department of Health
Sydney
NSW
Abstract
Objectives To determine the proportion of people in New South Wales towns at high risk of Japanese encephalitis virus (JEV) infections during the 2022 outbreak; to identify risk factors for JEV infection.
Study design Cross‐sectional serosurvey study of the seroprevalence of JEV‐specific antibodies in NSW.
Setting, participants Convenience sample of people (all ages) from five regional NSW towns deemed to be at high risk of JEV...
To continue reading this article in Full-Text...
Join the Valneva community to receive personalized information as specified in the Valneva Privacy Policy available here about Valneva services, product events and programs by email.
I WANT TO BE A MEMBER
Search | Advanced search
Articles by topics
